ReviewCancers2020
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Immunocyte senescence: A new perspective on the remodeling of the ovarian cancer microenvironment and therapeutic intervention.Journal of pharmaceutical analysis · 2026Review
- Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy.Materials today. Bio · 2026Article
- Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer.ImmunoHorizons · 2026Article
- Gynecologic management of cervical cancer patients undergoing immunotherapy: an up-to-date narrative review.Gynecology and pelvic medicine · 2026Review
- Article
- PD-L1 expression in pancreaticobiliary adenosquamous carcinoma: a single-institution case series.Journal of gastrointestinal oncology · 2024Article
- Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.Current treatment options in oncology · 2024Review
- Predictive Value of Magnetic Resonance Imaging in Risk Stratification and Molecular Classification of Endometrial Cancer.Cancers · 2024Article
- Aneuploid serves as a prognostic marker and favors immunosuppressive microenvironment in ovarian cancer.Journal of ovarian research · 2024Article
- A risk model based on 10 ferroptosis regulators and markers established by LASSO-regularized linear Cox regression has a good prognostic value for ovarian cancer patients.Diagnostic pathology · 2024Article
- Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.Yonsei medical journal · 2023Article
- The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review.Life (Basel, Switzerland) · 2023Review
- Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2023Review
- Reprogramming the tumor microenvironment leverages CD8Molecular therapy oncolytics · 2023Article
- The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients.Cancers · 2022Review
- Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.Diseases (Basel, Switzerland) · 2022Article
- Blocking TIGIT/CD155 signalling reverses CD8Journal of translational medicine · 2022Article
- A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.Frontiers in pharmacology · 2022Review
- Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy.Frontiers in oncology · 2021Review
- Comprehensive Analysis Identifies Potential Ferroptosis-Associated mRNA Therapeutic Targets in Ovarian Cancer.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides an update on the current use of immune checkpoint inhibitors (ICI) in female gynecologic cancers, and it addresses the potential of these agents to provide therapy options for disease management and long-term remission in advanced disease patients, where surgery, chemotherapy, and/or radiation fail to meet this goal. The topic of immune checkpoint inhibitors (ICI) blocking cytotoxic T lymphocyte associated protein-4 (CTLA-4) and the programmed death-1 (PD-1) axis has come to the forefront of translational medicine over the last decade for several malignancies. The text will focus primarily on a discussion of ovarian cancer, which is the most frequent cause of death of gynecologic cancers; endometrial cancer, which is the most often diagnosed gynecologic cancer; and cervical cancer, which is the third most common female gynecologic malignancy, all of which unfavorably alter the lives of many women. We will address the critical factors that regulate the outcome of these cancer types to ICI therapy, the ongoing clinical trials in this area, as well as the adverse immune responses that impact the outcome of patients given ICI regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.